2016•JAMA Internal MedicineRequires access

Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints

Tracy L. Rupp, Diana M. Zuckerman

Open publisher page 75 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 75 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Medicine, Surrogate endpoint, Cancer drugs, Quality of life (healthcare), Intensive care medicine, Drug approval, Endpoint Determination, Clinical endpoint

Back to paper search Browse research topics Original source

Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints — Research Paper | ScholarLens